Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Sangamo Therapeutics, Inc as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 193
- +2 vs. Q3 2021
- Shares held
- 76.9M
- +2.59M (+3.5%) vs. Q3 2021
- Total value
- $577.0M
- −$93.7M (−14.0%) vs. Q3 2021
- New holders
- 30
- 59 more added
- Sold out
- 28
- 59 more reduced
2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SGMOQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 6 | $29.0K |
| Q1 2026 | 112 | $26.0M |
| Q4 2025 | 105 | $26.2M |
| Q3 2025 | 112 | $42.1M |
| Q2 2025 | 114 | $39.6M |
| Q1 2025 | 122 | $34.5M |
| Q4 2024 | 128 | $62.9M |
| Q3 2024 | 103 | $48.6M |
| Q2 2024 | 129 | $31.1M |
| Q1 2024 | 131 | $68.2M |
| Q4 2023 | 130 | $47.2M |
| Q3 2023 | 135 | $61.3M |
| Q2 2023 | 152 | $137.4M |
| Q1 2023 | 180 | $197.6M |
| Q4 2022 | 182 | $326.0M |
| Q3 2022 | 197 | $477.2M |
| Q2 2022 | 188 | $371.1M |
| Q1 2022 | 195 | $459.6M |
| Q4 2021 | 193 | $577.0M |
| Q3 2021 | 193 | $679.3M |
| Q2 2021 | 197 | $912.0M |
| Q1 2021 | 203 | $994.7M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Sangamo Therapeutics, Inc; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Winton Group Ltd | 0 | $0 | 0.00% | −25,197−100.0% | Sold out |
| M&G Investment Management Ltd | 0 | $0 | 0.00% | −22,734−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −22,158−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −22,012−100.0% | Sold out |
| Cresset Asset Management, LLC | 0 | $0 | 0.00% | −21,855−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −14,585−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −14,460−100.0% | Sold out |
| Blueshift Asset Management, LLC | 0 | $0 | 0.00% | −14,375−100.0% | Sold out |
| Walleye Capital LLC | 0 | $0 | 0.00% | −11,465−100.0% | Sold out |
| KBC Group NV | 0 | $0 | 0.00% | −11,300−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −3,325−100.0% | Sold out |
| Evoke Wealth, LLC | 0 | $0 | 0.00% | −1,250−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −1,050−100.0% | Sold out |
| Cahill Financial Advisors Inc | 0 | $0 | 0.00% | −316−100.0% | Sold out |
| O'Shaughnessy Asset Management, LLC | 0 | $0 | 0.00% | −158−100.0% | Sold out |
| NEXT Financial Group, Inc | 0 | $0 | 0.00% | −89−100.0% | Sold out |
| PrairieView Partners, LLC | 0 | $0 | 0.00% | −70−100.0% | Sold out |
| First Horizon Advisors, Inc. | 0 | $0 | 0.00% | −41−100.0% | Sold out |
| Cordant, Inc. | 0 | $0 | 0.00% | −54−100.0% | Sold out |
| Gerber Kawasaki Wealth & Investment Management | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Alexandria Capital, LLC | – | – | – | – | Not filed |
| Berman Capital Advisors, LLC | – | – | – | – | Not filed |